Page 34 - Pfizer

Early studies of potential coronavirus treatment show promise: Pfizer

It also finalised a plan to develop a coronavirus vaccine in partnership with German drugmaker BioNTech SE and said the companies hope to produce millions of vaccines by the end of 2020.

Big Pharma's addiction to profit

Book review of PHARMA: Greed, Lies, and the Poisoning of America

Pfizer may work with BioNTech to develop coronavirus vaccine: R&D head

(Reuters) - Pfizer Inc is considering a collaboration with German drugmaker BioNTech SE <22UAy.F> to develop vaccines for the coronavirus using BioNTech's mRNA-based drug development platform, Pfizer's R&D head told Reuters on Thursday.

Pfizer warns of hit to financial results on continued coronavirus outbreak

The outbreak that began in Wuhan at the end of last year has killed over 2,700 in China, with over 78,000 confirmed cases of infection, and has now spread to several other countries.

Pfizer Q3 net profit climbs 5%, operational revenue up at Rs 514 cr

The company had posted a net profit of Rs 131.94 crore for the corresponding period of the previous fiscal, Pfizer Ltd said in a filing to BSE.

Pfizer planning initial public offering of GSK consumer venture in four yrs

Albert Bourla, CEO of Pfizer, discussed the time frame for the IPO at the JPMorgan Healthcare Conference in San Francisco on Tuesday

Legacy pharma brands spin gold for GSK, Pfizer; keep newcomers off the turf

Repositioning an old brand helps expand the footprint, say analysts

Drugmakers from Pfizer to GSK to hike US prices up to 10% on over 200 drugs

More price increases are expected to be announced later this week, which could affect the median and range.

Caplin Steriles gets US FDA approval for generic blood pressure drug

The company has so far developed and filed 13 ANDAs on its own and with partners, and received six approvals

Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge

Excluding special items, Pfizer earned 75 cents per share, topping analysts' average estimate by 13 cents

Biocon subsidiary acquires research facility from Pfizer Healthcare

Biotechnology major Biocon on Tuesday said its subsidiary has acquired a Chennai-based biological research facility from Pfizer Healthcare for an undisclosed amount. Biocon Biologics has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai, Biocon said in a statement. The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide," Biocon Biologics CEO Christiane Hamacher said. This investment will allow the company to fast-forward development of its biosimilars from lab to pilot scale, he added. The facility will house an early stage research and innovation centre, including a pilot scale R&D unit equipped with cell line development, drug product formulation laboratories and analytical R&D laboratories. The facility is ...

Sebi imposes Rs 22.7 crore fine on Aurobindo Pharma for insider trading

The order said that the penalty amount will be paid within 45 days of receipt of this order

Pfizer may be talks to merge off-patent drugs business with Mylan

Separation of Pfizer's off-patent business would be a tax-free spin-off

Pfizer offers severance package to employees of Chennai, Aurangabad units

The package offers statutory bonus, gratuity and a compensation of 75 days' wages for every completed year of service. An early bird incentive of Rs 7 lakh has also been offered

Aurangabad, Chennai plants may be sold, not shut: Pfizer tells employees

Both sites will immediately cease manufacturing; the company will exit both sites as soon as possible.

Pfizer to stop manufacturing operations in Chennai, Aurangabad units

Over 1,700 employees were working in these two facilities

Pfizer Q2 profit dips 13.81% to Rs 958 million, revenue drops marginally

Revenue from operations of the company stood at Rs 5.19 billion in the quarter

Pfizer cuts revenue forecast on supply shortage at sterile-injections biz

Pfizer has been tackling supply shortage issues at its sterile injectable products unit for at least a year

Pfizer replaces long-time CEO Ian Read with veteran Albert Bourla

Pfizer is contending with the expiry of patents on some of its blockbuster drugs

Pfizer stops production at Tamil Nadu plant after 11 USFDA observations

Firm says it is disappointed with the outcome of the inspection